Key Insights

Highlights

Treatment Research

1 treatments under study, led by Olaparib

Research Leaders

5 sponsors active, led by Merck Sharp & Dohme LLC

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT01844986Phase 3Active Not Recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Showing all 1 trials

Research Network

Common Treatments

  • Olaparib1

Active Sponsors

  • Merck Sharp & Dohme LLC1
  • Myriad Genetic Laboratories, Inc.1
  • Astrazeneca AB1
  • AstraZeneca1
  • GOG Foundation1

Top Investigators

Related Conditions

  • Newly Diagnosed1
  • Partial Response1
  • Figo Stage Iiiiv1
  • Advanced Ovarian Cancer1
  • Brca Mutation1

Activity Timeline